Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Pimentel, Mark ^a   Morales, Walter ^a   Rezaie, Ali ^a   Marsh, Emily ^a   Lembo, Anthony ^b   Mirocha, James ^a   Leffler, Daniel A ^b   Marsh, Zachary ^a   Weitsman, Stacy ^a   Chua, Kathleen S ^a   Barlow, Gillian M ^a   Bortey, Enoch ^c   Forbes, William ^c   Yu, Allen ^a   Chang, Christopher ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOLETHAL DISTENDING TOXIN B ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VINCULIN ANTIBODY; AUTOANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CELIAC DISEASE; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OPTICAL DENSITY; PATIENT SELECTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; VALIDATION PROCESS; ADOLESCENT; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; VALIDATION STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; BIOMARKERS; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; DIARRHEA; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; ROC CURVE; YOUNG ADULT;

EID: 84929340217     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126438     Document Type: Article

References (47)

1. Hill ID. What are the sensitivity and specificity of serologic tests for celiac disease? Do sensitivity and specificity vary in different populations? Gastroenterology 2005; 128: S25-32. PMID: 15825123
2. Kruis W, Thieme C, Weinzierl M, Schussler P, Holl J, Paulus W. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984; 87: 1-7. PMID: 6724251
3. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2: 653-654. PMID: 698649
4. Thompson WG, Dotevall G, Drossman DA, Heaton KW, Kruis W. Irritable bowel syndrome: Guidelines for diagnosis. Gastroenterol Int 1989; 2: 92-95.
5. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 Suppl 2: II43-47. PMID: 10457044
6. Foundation Rome. Guidelines - Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders. J Gastrointestin Liver Dis 2006; 15: 307-312. PMID: 17203570
7. Drossman DA, Sandler RS, McKee DC, Lovitz AJ. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology 1982; 83: 529-534. PMID: 7095360
8. Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci 2010; 55: 2441-2449. doi: 10.1007/s10620-010-1276-4 PMID: 20467896
9. Posserud I, Stotzer PO, Bjornsson ES, Abrahamsson H, Simren M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007; 56: 802-808. PMID: 17148502
10. Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci 2012; 57: 1321-1329. doi: 10.1007/s10620-012-2033-7 PMID: 22262197
11. Pimentel M, Funari V, Giamarellos-Bourboulis EJ, Pyleris E, Pistiki K, Tang J et al. The First Large Scale Deep Sequencing of the Duodenal Microbiome in Irritable Bowel Syndrome Reveals Striking Differences Compared to Healthy Controls. Scand J Gastro 2013; in press
12. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome - a meta-analysis. Am J Gastroenterol 2006; 101: 1894-1899; quiz 1942. PMID: 16928253
13. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535-544. PMID: 17661757
14. Shah ED, Riddle MS, Chang C, Pimentel M. Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome. J Neurogastroenterol Motil 2012; 18: 200-204. doi: 10.5056/jnm.2012.18.2.200 PMID: 22523730
15. Pimentel M, Chatterjee S, Chang C, Low K, Song Y, Liu C, et al. A new rat model links two contemporary theories in irritable bowel syndrome. Dig Dis Sci 2008; 53: 982-989. PMID: 17934822
16. Jee SR, Morales W, Low K, Chang C, Zhu A, Pokkunuri V, et al. ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. World J Gastroenterol 2010; 16: 3680-3686. PMID: 20677340
17. Morales W, Pimentel M, Hwang L, Kunkel D, Pokkunuri V, Basseri B, et al. Acute and chronic histological changes of the small bowel secondary to C. jejuni infection in a rat model for post-infectious IBS. Dig Dis Sci 2011; 56: 2575-2584. doi: 10.1007/s10620-011-1662-6 PMID: 21409374
18. Pokkunuri V, Pimentel M, Morales W, Jee SR, Alpern J, Weitsman S, et al. Role of Cytolethal Distending Toxin in Altered Stool Form and Bowel Phenotypes in a Rat Model of Post-infectious Irritable Bowel Syndrome. J Neurogastroenterol Motil 2012; 18: 434-442. doi: 10.5056/jnm.2012.18.4.434 PMID: 23106005
19. Morales W, Weitsman S, Kim G, Marsh E, Chang C, Pimentel M. Circulating antibodies to cytolethal distending toxin B correlate with the development of small intestinal bacterial overgrowth in a rat model of post-infectious IBS. Gastroenterology 2013; 144: S-931-932.
20. Pimentel M, Morales W, Pokkunuri V, Brikos C, Kim SM, Kim SE, et al. Autoimmunity links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes following Campylobacter jejuni Infection in a Rat Model. Dig Dis Sci (2014); Nov 26. [Epub ahead of print].
21. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845. PMID: 3203132
22. Pimentel M, Talley NJ, Quigley EM, Hani A, Sharara A, Mahachai V. Report from the multinational irritable bowel syndrome initiative 2012. Gastroenterology 2013; 144: e1-5.
23. Cash BD, Chey WD. Irritable bowel syndrome - an evidence-based approach to diagnosis. Aliment Pharmacol Ther 2004; 19: 1235-1245. PMID: 15191504
24. Vitoria JC, Arrieta A, Arranz C, Ayesta A, Sojo A, Maruri N, et al. Antibodies to gliadin, endomysium, and tissue transglutaminase for the diagnosis of celiac disease. J Pediatr Gastroenterol Nutr 1999; 29: 571-574. PMID: 10554125
25. Porter CK, Thura N, Riddle MS. Quantifying the incidence and burden of postinfectious enteric sequelae. Mil Med 2013; 178: 452-469. doi: 10.7205/MILMED-D-12-00510 PMID: 23707833
26. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-811. PMID: 11076879
27. Mearin F, Perez-Oliveras M, Perello A, Vinyet J, Ibanez A, Coderch J, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005; 129: 98-104. PMID: 16012939
28. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004; 99: 1774-1778. PMID: 15330917
29. Ji S, Park H, Lee D, Song YK, Choi JP, Lee SI. Post-infectious irritable bowel syndrome in patients with Shigella infection. J Gastroenterol Hepatol 2005; 20: 381-386. PMID: 15740480
30. Pickett CL, Whitehouse CA. The cytolethal distending toxin family. Trends Microbiol 1999; 7: 292-297. PMID: 10390639
31. Smith JL, Bayles DO The contribution of cytolethal distending toxin to bacterial pathogenesis. Crit Rev Microbiol 2006; 32: 227-248. PMID: 17123907
32. Frisk A, Lebens M, Johansson C, Ahmed H, Svensson L, Ahlman K, et al. The role of different protein components from the Haemophilus ducreyi cytolethal distending toxin in the generation of cell toxicity. Microb Pathog 2001; 30: 313-324. PMID: 11399138
33. Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nat Rev Mol Cell Biol 2010; 11: 633-643. doi: 10.1038/nrm2957 PMID: 20729930
34. Peng X, Cuff LE, Lawton CD, DeMali KA. Vinculin regulates cell-surface E-cadherin expression by binding to beta-catenin. J Cell Sci 2010; 123: 567-577. doi: 10.1242/jcs.056432 PMID: 20086044
35. Peng X, Nelson ES, Maiers JL, DeMali KA. New insights into vinculin function and regulation. Int Rev Cell Mol Biol 2011; 287: 191-231. doi: 10.1016/B978-0-12-386043-9.00005-0 PMID: 21414589
36. Demali KA. Vinculin - a dynamic regulator of cell adhesion. Trends Biochem Sci 2004; 29: 565-567. PMID: 15501673
37. Xu W, Baribault H, Adamson ED. Vinculin knockout results in heart and brain defects during embryonic development. Development 1998; 125: 327-337. PMID: 9486805
38. Zemljic-Harpf AE, Ponrartana S, Avalos RT, Jordan MC, Roos KP, Dalton ND, et al. Heterozygous inactivation of the vinculin gene predisposes to stress-induced cardiomyopathy. Am J Pathol 2004; 165: 1033-1044. PMID: 15331426
39. Varon C, Mocan I, Mihi B, Pere-Vedrenne C, Aboubacar A, Morate C, et al. Helicobacter pullorum cytolethal distending toxin targets vinculin and cortactin and triggers formation of lamellipodia in intestinal epithelial cells. J Infect Dis 2014; 209: 588-599. doi: 10.1093/infdis/jit539 PMID: 24470577
40. Izard T, Tran Van Nhieu G, Bois PR. Shigella applies molecular mimicry to subvert vinculin and invade host cells. J Cell Biol 2006; 175: 465-475. PMID: 17088427
41. Tsuchiya N, Williams RC Jr. Molecular mimicry-hypothesis or reality? West J Med 1992; 157: 133-138. PMID: 1279899
42. Leffler DA, Dennis M, Hyett B, Kelly E, Schuppan D, Kelly CP. Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol 2007; 5: 445-450. PMID: 17382600
43. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 450-460. PMID: 12145798
44. Mooiweer E, Severs M, Schipper ME, Fidder HH, Siersema PD, Laheij RJ, et al. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis 2015; 9: 50-55. doi: 10.1093/ecco-jcc/jju003 PMID: 25518048
45. Park JM, Choi M- G, Paik CN, Oh JH, Cho YK, Lee IS, et al. Clinical Significance of Anti-tissue Transglutaminase as a Screening Method for Celiac Disease in a Korean Population. Kor J Neurogastroenterol Motil 2006; 12: 35-40.
46. Stanisic V, Quigley EM. The overlap between IBS and IBD: what is it and what does it mean? Expert Rev Gastroenterol Hepatol 2014; 8: 139-145. doi: 10.1586/17474124.2014.876361 PMID: 24417262
47. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 1474-1482. doi: 10.1038/ajg.2012.260 PMID: 22929759